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Quantitative Assessment of Fibrinogen Cross-Linking
by Aminocaproic Acid in Patients With End-Stage
Liver Disease
Thien Quach,1 Melissa Tippens,1 Fania Szlam,2 Rebecca Van Dyke,1
Jerrold H. Levy,2 and Marie Csete1,2
Analysis of the effectiveness of antifibrinolytic therapy for
liver transplant recipients is hampered by lack of quanti-
tative assays for assessing drug effects. We adapted chem-
ical engineering tools used in polymerization studies to
quantify fibrinogen cross-linking by plasma from liver
transplant patients obtained before and after aminocap-
roic acid (EACA) therapy. A target fluorescein isothiocya-
nate–fibrinogen (FITC—fibrinogen) molecule was con-
structed; it fluoresces in a quantifiable pattern when in
solution, and undergoes cross-linking in the presence of
plasmin inhibitors. Cross-linking quenches the fluores-
cent signal, and the quenching is a quantifiable endpoint.
Thus fluorescence from this reporter molecule can be used
to assess functional improvement in fibrinogen cross-link-
ing as a result of antifibrinolytic therapies, and it is sensi-
tive to picomolar amounts of plasmin inhibitors and acti-
vators. Cross-linking of FITC-fibrinogen by patient
plasma, before and after EACA therapy, was assessed using
fluorescence spectrometry. Fluorescence patterns from
FITC-fibrinogen indicated no significant cross-linking of
the target fibrinogen as a consequence of EACA in post-
treatment plasma. When the fibrinogen-FITC target was
assayed without plasma in the presence of EACA at con-
centrations that bracket therapeutic levels (100 and 400
g/ml), significant fluorescence quenching (target FITC-
fibrinogen cross-linking) was achieved. These results sug-
gest that fibrinogen-FITC fluorescence is sensitive enough
to detect EACA activity in clinically relevant ranges, but
that EACA given in usual doses is insufficient to promote
fibrinogen cross-linking in patients with end-stage liver
disease. (Liver Transpl 2004;10:123–128.)
End-stage liver disease (ESLD) is often associatedwith low-grade primary fibrinolysis, a complica-
tion of liver failure recognized almost a century ago.1,2
A recent study, for example, suggests that about a third
of cirrhotic patients have hyperfibrinolysis as assessed
by shortened euglobulin lysis times.3 Furthermore,
worsening of primary fibrinolysis is a well-known
superimposed complication of liver transplantation,
characteristically most pronounced after reperfusion of
the graft.4 Antifibrinolytic therapy is used by many
transplant anesthesiologists to prevent or respond to
fibrinolysis during liver transplantation, though the
details of antifibrinolytic therapy differ considerably
from center to center. Epsilon-aminocaprioic acid
(EACA) has a long history of use during liver transplan-
tation, and its empiric use has been generally safe and
well tolerated. Dosing regimens for EACA are based on
observational studies that were not blinded or con-
trolled, or in which intraoperative transfusion was used
as the primary endpoint for analysis.5,6 Furthermore,
dosing regimens adapted for use during liver transplan-
tation are based on those established for patients with-
out liver disease, and do not account for markedly
altered volume of distribution in patients with ESLD.7
Recognizing the lack of reliable endpoints for anti-
fibrinolytic therapy, this study describes the first
attempts to develop a new quantitative assay for study-
ing the effectiveness of EACA therapy in patients
undergoing liver transplantation. Human fibrinogen
was labeled with the fluorescent marker fluorescein iso-
thiocyanate (FITC). The labeled FITC-fibrinogen
exhibits a predictable fluorescence pattern, which is
quenched when the fibrinogen is cross-linked due to
close proximity of the fluorescent FITC molecules.8 On
the other hand, fluorescence of the engineered target
molecule increases (dequenches) with disruption of the
fibrinogen cross-linking (fibrinolysis).9 Thus the fluo-
rescence pattern is a quantitative indicator of fibrinogen
cross-linking, and is sensitive enough to detect even
picomolar levels of plasminogen activators and inhibi-
tors.10 Here we describe preliminary results using this
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novel assay to quantitate EACA effectiveness in patients
presenting for liver transplantation.
Patients and Methods
Blood Collection
This study was approved by the University of Michigan Insti-
tutional Review Board, and informed consent in writing was
obtained from all patients. All adult liver-transplant patients
were suitable for study, except those with fulminant hepatic
failure or history of thrombosis. After induction of general
anesthesia, a radial arterial catheter was placed. A baseline
(pre-EACA) blood sample was drawn from the arterial cath-
eter (20 ml). All blood samples were collected into plastic
centrifuge tubes, stored on ice until centrifugation, 1,300 g
for 5 minutes, then the plasma was stored at 80°C until
assay. EACA was administered, 5 g bolus followed by 1 g/hr
IV infusion. At the end of this hour (during which vascular
access was established, and before surgical incision), the sec-
ond blood sample was obtained. Demographic data from each
patient were collected at the time of study from the hospital
record.
FITC-Fibrinogen Labeling
FITC (Molecular Probes, Eugene, OR), 10 mg/ml, and
human fibrinogen (Enzyme Research Labs, South Bend, IN),
10 mg/ml, were incubated at 22°C in 0.1 M sodium bicar-
bonate (pH 9.0) for one hour with stirring. Addition of
hydroxylamine (0.15 M final) stopped the reaction. Unbound
FITC molecules were removed via dialysis in 0.1 sodium
bicarbonate (pH 9.0) at 4°C overnight. The solution was
transferred to 100,000 molecular weight cutoff (MWCO)
cellulose-ester tubing (Spectrum Laboratories, Rancho
Dominguez, CA) and dialyzed overnight with two buffer
changes of 1.5 L each. Final product concentration was
assayed at 280 nm with a Beckman DU530 Spectrophotom-
eter and then stored at 80oC.
Fluorometry
A Perkin-Elmer LS-50B fluorometer was used for fluores-
cence assays. Scanning was performed at 488 nm excitation
and 520 nm emission wavelengths and a slit width of 5 mm,
and FITC-fibrinogen concentration of 2 mg/ml. Cuvettes
were preincubated with 2 mg/ml bovine serum albumin
(Sigma, St Louis, MO) for at least 30 minutes prior to use to
minimize substrate adherence to cuvette walls. For each reac-
tion, reagents were added to the cuvette in the following
order: 10 buffer (final concentration: 0.1 M NaC1, 0.05 M
Tris-HC1, 5 mM CaC12); water to normalize volume; FITC-
fibrinogen; plasmin (0.5 mg/ml (American Diagnostica,
Greenwich, CT); then EACA or plasma, depending on the
assay. Thirty microliters of plasma were used per sample. Data
were collected for 1,200 seconds.
Statistical Analysis
Curve slopes were calculated using computer algorithms.
Comparisons of slopes generated by pre- and post-EACA
plasma samples added to the target FITC-fibrinogen were
done using paired t tests, with P  0.05 considered a signifi-
cant difference. Slopes were analyzed over several different
times in the reaction, in order to more fully characterize the
fibrinogen cross-linking potency of plasma before and after
EACA administration. Data are presented as mean  stan-
dard deviation (SD), except as noted.
HPLC Measurement of Plasma EACA Levels
High-pressure liquid chromatography (HPLC) for EACA was
performed based on published protocols with some modifica-
tions.12,13 One hundred microliters of plasma (containing tran-
examic acid as an internal standard) were analyzed. Ten microli-
ters of 10% zinc sulfate was added, followed by 100 l of
acetonitrile. After mixing and centrifugation, 50 l of clear
supernatant was transferred to an injection vial containing 300
l borate buffer. Just prior to injection, 50 l of OPA (20mg
o-phtalaldehyde and 25 mg N-acetyl-L cysteine in 6mL 50%
methanol/water) was added for derivatization. The derivatized
sample was separated on a 15  4.6 cm Nucleosil 5, C18 col-
umn, and eluted with a mobile phase consisting of 13% aceto-
nitrile in buffer (copper sulfate, proline, and ammonium acetate)
and delivered at 2 ml/min. The OPA derivative of EACA was
monitored using a fluorescence detector (Shimadzu 551) set at
252 nm (excitation) and 450 nm (emission).
ELISA Measurement of D-dimer Levels
D-dimer levels in plasma samples were quantitated by enzyme
linked immunosorbent assay (ELISA) using a commercial kit
according to the manufacturer’s instructions (Diagnostica
Stago, Asnières, France). The normal D-dimer level in this
assay is 400 ng/ml.
Results
Demographic Data on Study Patients
Mean age of the patients was 46  10 years. Two were
women, and eight were men. Four patients had hepati-
tis C; four patients had hepatitis C and alcoholic cirrho-
sis; one patient had hepatitis B; and one patient was
transplanted for primary sclerosing cholangitis. Com-
plete blood count and coagulation profiles (mean 
SD.) are shown in Table 1. As expected, patients were
thrombocytopenic, and coagulation profiles were con-
sistent with moderate hepatic synthetic dysfunction.
FITC-Fibrinogen Fluorescence is Quenched by
Therapeutic Concentrations of EACA
The sensitivity of the FITC-fibrinogen reporter system
was assayed by adding EACA (Abbott Laboratories,
Abbott Park, IL) at 100 g/ml or 400 g/ml to the
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FITC-fibrinogen target molecule in the presence of
plasmin. These EACA concentrations were chosen
because they bracket the manufacturer’s recommended
therapeutic concentration (130 g/ml) as well as ther-
apeutic concentration (260 g/ml) suggested for chil-
dren undergoing cardiopulmonary bypass, where an
increased volume of distribution is assumed.11 Further-
more, the assay used in this study is sensitive to 0.1 to 10
mM EACA, well below the levels achieved in plasma.9
EACA at either 100 or 400 g/ml significantly
increased fibrinogen cross-linking as assessed by fluo-
rescence emission slope patterns, and there was more
quenching of fluorescence (more cross-linking) at the
higher concentration of EACA than the lower (Fig. 1).
Usual Doses of EACA Do Not Result in
Enhanced Fibrinogen Cross-Linking by
Plasma In Vitro
Analysis of fluorescence patterns revealed that maxi-
mum quenching (indicating maximum fibrinogen
cross-linking) occurred early in the reaction after addi-
tion of plasma to the FITC-fibrinogen target in the
presence of plasmin. The fluorescence quenching data
are presented in Table 2, showing the calculated slopes
Table 2. Slopes of Curves Generated by Fluorometric
Analysis of FITC-Fibrinogen Signaling in the Presence of
Patient Plasma Before and After EACA Treatment





300–400 1.74  0.54 2.49  0.65 0.72
300–500 1.21  0.30 1.49  0.41 0.66
300–700 1.05  0.24 1.25  0.31 0.30
FITC-fibrinogen cross-linking was assessed in the presence of
plasma from ESLD patients collected before and after EACA
(5 g bolus followed by a 1 g/hr intravenous infusion). In this
assay, increased fibrinogen cross-linking is indicated by a
reduction in slope (quenching). Plasma after EACA treat-
ment did not significantly alter fibrinogen cross-linking com-
pared to baseline plasma, as assesed by paired t testing.
Figure 1. Fluorescence patterns of FITC-fibrinogen in
the presence of plasmin and EACA. Y axis is arbitrary
fluorescence units; x axis is time in seconds. EACA con-
centrations of 100 g/ml and 400 g/ml, which bracket
recommended therapeutic levels, both quench the fluores-
cence signal. Slopes (m) were measured over the first 200
seconds of the reaction. Significant cross-linking of the
target FITC-fibrinogen construct occurs in the presence of
100 or 400 g/ml EACA, confirming sensitivity of the
assay.
Figure 2. Fluorescence pattern of FITC-fibrinogen gener-
ated in the presence of plasma before EACA treatment,
and after EACA. The two signals are virtually indistin-
guishable, indicating no change in target fibrinogen cross-
linking after treatment. Slope (m) was calculated over the
first 200 seconds of the reaction.
Table 1. Preoperative Blood Count and Coagulation
Profiles of Study Patients
Mean SD
Hemoglobin (g/dl) 11.0 0.8
Hematocrit (%) 32.5 5.1
Platelets (/mm3) 64,000 21,000
Prothrombin time (s) 14.3 1.7
Int’l normalized ratio 1.44 0.3
Partial thromboplastin time (s) 40.8 10.0
Fibrinogen (mg/dl) 160 47
Abbreviation: s, second. Laboratory data from study patients
undergoing liver transplantation (n  10) just prior to sur-
gery.
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integrated over various times in the reaction. A repre-
sentative assay from a single patient’s samples is
depicted in Figure 2, illustrating the time-course of a
typical in vitro fluorescence quenching reaction. In Fig-
ure 2, the pre-EACA plasma and post-EACA plasma of
a single patient were not different from each other. Not
only was there no significant increase in fibrinogen
cross-linking induced by plasma after EACA therapy on
average, but also in some patients the post-treatment
plasma actually caused dequenching of the baseline sig-
nal.
EACA, 5 g Bolus then 1 g/hr Infusion,
Achieves “Therapeutic” Plasma
Concentration in Patients With ESLD,
Despite Increased Volume of Distribution
To determine whether subtherapeutic drug levels con-
tributed to the lack of potency in fibrinogen cross-
linking, EACA plasma levels were measured. All pre-
EACA (baseline) plasma samples contained no EACA
by HPLC. The range of levels in posttreatment plasma
was 207 to 501 ug/ml with a mean of 346  36 ug/ml
(SE). These levels approximate those considered thera-
peutic in other surgical settings.
D-Dimer Levels Before and After EACA
D-dimer levels varied widely at baseline, but did not
change significantly in post-EACA plasma samples.
Mean D-dimer levels were 1,554  524 (SE) at base-
line, and were 2,253  664 ng/ml after EACA (P 
0.21).
Discussion
The study represents a first step in developing quanti-
tative methodologies for studying antifibrinolytic
drugs, with a long-term goal of using this methodology
to refine antifibrinolytic therapy for patients with end-
stage liver disease undergoing liver transplantation.
Details about the aberrations in pharmacokinetics and
pharmacodynamics of drugs used in the intraoperative
care of cirrhotic patients are remarkably limited, partly
because these patients often have disordered renal and
cardiac function and are inherently difficult to study.14
EACA is not an exception to this information void,
despite its potential importance in liver transplantation.
Though many transplant anesthesiologists feel that
EACA (or the related lysine analog antifibrinolytic,
tranexamic acid) plays an important role in preventing
blood loss during liver transplantation, EACA has not
been formally studied with objective, quantitative end-
points of its effectiveness in this setting.15 Furthermore,
studies on antifibrinolytic drugs during liver transplan-
tation have been difficult to interpret because of meth-
odological limitations (historic controls, small numbers
of patients, wide patient variability in bleeding risk,
varied experience of the transplant teams) as reviewed in
Kufner.16 The most influential study supporting the use
of EACA during transplantation was not controlled,
but it suggested that EACA 1 g should be given as
needed with thrombelastographic evidence of fibrino-
lysis.5 Twenty patients were treated in this study. A
subsequent retrospective analysis of 36 patients (15
received EACA) showed no benefit to using EACA in
preventing blood loss during liver transplantation.17 A
later description of clinical experience (without data
presented) suggested that doses as low as 250 mg
(instead of 1 g) could be used in response to thrombelas-
tographic evidence of fibrinolysis.18 Only one blinded,
prospective analysis of EACA has been reported in the
liver transplant literature. In this report, 42 liver trans-
plant patients received EACA (6 mg/hr), and 40 did
not. EACA reduced transfusion requirements but not
significantly.6 Taken together, EACA has been formally
studied in very few liver transplant patients, and the
published endpoints of analysis in these studies are dif-
ficult to interpret. Furthermore, all studies to date have
used fixed dosing regimens, though the degree of fibri-
nolysis during transplantation is widely variable and
likely to require widely varying dosages of antifibrino-
lytic therapy. Development of methods as presented in
this study, combined with rigor in study design as well
as larger studies, may be useful to readdress the value of
antifibrinolytic therapies in liver transplant recipients.
Patients with end-stage liver disease have both an
effective increase in total blood volume and an
increased volume of distribution for highly water-solu-
ble drugs.19 The increase in volume of distribution has
been best characterized for neuromuscular blockers and
was first recognized for d-tubocurarine.20 For example,
patients with end-stage liver disease have an estimated
50% increase in the volume of distribution for pancu-
ronium.21
Though the pharmacokinetics of EACA in end-
stage liver disease patients have not been directly
addressed, investigations in other surgical populations
may be informative for liver transplant recipients.
Recently EACA pharmacokinetics have been studied
and modeled extensively in patients undergoing cardio-
pulmonary bypass. These patients also develop fibrino-
lysis during surgery, though the molecular mechanisms
underlying fibrinolysis during cardiopulmonary bypass
and during liver transplantation are likely to be differ-
ent. Nonetheless, cardiopulmonary bypass patients,
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like those undergoing liver transplantation, have
increased volume of distribution for EACA such that
these studies may be somewhat informative for cirrhotic
patients. Based on measurement of EACA levels and
pharmacokinetic models, Butterworth found that a
loading dose of 70 mg/kg followed by an infusion of 30
mg/kg/hr would maintain EACA levels at approxi-
mately theoretical therapeutic concentration in patients
undergoing cardiopulmonary bypass.22 This recom-
mended loading dose is approximately the same used in
our study, but the recommended infusion rate is about
twice that used in our study. Our results indicate that
approximately the same levels of drug are achieved in
patients with ESLD as in those undergoing cardiopul-
monary bypass.
Nonetheless, the new assay used in this study sug-
gested that EACA at these plasma levels has no func-
tional antifibrinolytic effect on average in patients with
ESLD. When data from individual patients are ana-
lyzed, however, some patients showed increased fibrin-
ogen cross-linking in response to EACA, though most
did not. Similarly, clinicians who use thrombelastogra-
phy to monitor EACA therapy can detect wide variance
in the qualitative response to therapy. Our pooled data
suggest that this EACA dose (and plasma levels) may
not be sufficient for a functional effect on plasminogen
and plasmin to effect fibrinogen cross-linking, and
more drug may be required in patients with ESLD.
Furthermore, the data suggest that the risk of inducing
too much procoagulant effect is unlikely using EACA in
patients with ESLD. One theoretical issue raised by the
results is the possibility that functional inhibitors of
plasmin are present in the plasma of patients with end-
stage liver disease. These issues require further study in
order to optimize intraoperative antifibrinolytic ther-
apy.
D-dimer levels are used to monitor EACA therapy in
some surgical settings (for example, cardiac surgery),
and the absence of an expected rise in D-dimers is
considered an indication that fibrinolysis has been
treated.23 Degradation of cross-linked fibrin causes
release of products that are measured in D-dimer assays.
These assays are used clinically to quantify of the
amount of active fibrin formation and lysis.24 In this
study, D-dimer levels suggested no antifibrinolytic
activity by the infused EACA, supporting the fluores-
cence assay. Although surgical incision was not made
before both sets of blood were collected, large bore
catheters including percutaneous venovenous bypass
lines were inserted during the hour of EACA therapy.
In some patients these procedures may have contrib-
uted to an increase in D-dimer levels over the hour of
EACA infusion. On average, D-dimer levels increased
during the EACA infusion, but not significantly so, a
pattern similar to that obtained fluorometrically in
FITC-fibrinogen cross-linking assay. Surprisingly,
D-dimer levels have not been reported as outcome
monitors for EACA therapy during liver transplanta-
tion, and thus the correlation between the FITC-fibrin-
ogen assay and D-dimer levels will also require further
study.
In conclusion, progress in modeling pharmacokinet-
ics and pharmacodynamics of EACA, as acknowledged
in published reports, is hindered by a lack of functional
studies to assess antifibrinolytic effectiveness.11,12 The
approach taken here can be used to augment our under-
standing of the optimal regimens for EACA not only in
liver transplant patients, but also in other patient pop-
ulations that may benefit from EACA therapy.
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